The efficacy of azathioprine in relapsing ‐ remitting multiple sclerosis
暂无分享,去创建一个
D. Goodkin | W. Beatty | W W Beatty | D E Goodkin | D Hertsgaard | Doris Hertsgaard | R C Bailly | M L Teetzen | R. Bailly | M. Teetzen
[1] British And Dutch Multiple Sclerosis Azathioprine Trial Group. DOUBLE-MASKED TRIAL OF AZATHIOPRINE IN MULTIPLE SCLEROSIS , 1988, The Lancet.
[2] L. Kinlen. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. , 1985, The American journal of medicine.
[3] F. Lhermitte,et al. NOT SO BENIGN LONG-TERM IMMUNOSUPPRESSION IN MULTIPLE SCLEROSIS? , 1984, The Lancet.
[4] D. Goodkin,et al. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.
[5] H. Weiner,et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.
[6] G. Ellison,et al. A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis , 1978, Neurology.
[7] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[8] Immunological Treatment in Multiple Sclerosis , 1980, The Lancet.
[9] A. Compston,et al. DOUBLE-BLIND CONTROLLED TRIAL OF IMMUNOSUPPRESSION IN THE TREATMENT OF MULTIPLE SCLEROSIS: FINAL REPORT , 1982, The Lancet.
[10] M. Nuwer,et al. Clinical experience with azathioprine: The pros , 1988, Neurology.
[11] H. Weiner,et al. MS: a CNS and systemic autoimmune disease. , 1989, Immunology today.
[12] M. R. Mickey,et al. A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis , 1989, Neurology.